



FDA Cardiologist's Perspective on RECORD

Joint Meeting of the Endocrinologic and Metabolic
Drugs Advisory Committee and the Drug Safety
and Risk Management Advisory Committee
Avandia® (rosiglitazone) – July 13-14, 2010

Ellis F. Unger, M.D.

Deputy Director,
Office of Drug Evaluation-I
Office of New Drugs (OND)
Center for Drug Evaluation and Research (CDER)
U.S. Food and Drug Administration

Outline of Presentation

- Why are we here?
- RECORD: Key features
- RECORD: Ascertainment bias
- Conclusions



Why are we here?

Nissen/Wolski Meta-analysis

The NEW ENGLAND
JOURNAL of MEDICINE

VOL. 356 NO. 24

JUNE 14, 2007

ESTABLISHED IN 1812

Effect of Rosiglitazone on the Risk of Myocardial Infarction
and Death from Cardiovascular Causes

Steven E. Nissen, M.D., and Kathy Wolski, M.P.H.

Nissen/Wolski Meta-analysis

Table 4. Rates of Myocardial Infarction and Death from Cardiovascular Causes.

Study	Rosiglitazone Group <i>no. of events/total no. (%)</i>	Control Group <i>no. of events/total no. (%)</i>	Odds Ratio (95% CI)	P Value
Myocardial infarction				
Small trials combined	44/10,285 (0.43)	22/6106 (0.36)	1.45 (0.88–2.39)	0.15
DREAM	15/2,635 (0.57)	9/2634 (0.34)	1.65 (0.74–3.68)	0.22
ADOPT	27/1,456 (1.85)	41/2895 (1.42)	1.33 (0.80–2.21)	0.27
Overall			1.43 (1.03–1.98)	0.03
Death from cardiovascular causes				
Small trials combined	25/6,845 (0.36)	7/3980 (0.18)	2.40 (1.17–4.91)	0.02
DREAM	12/2,635 (0.46)	10/2634 (0.38)	1.20 (0.52–2.78)	0.67
ADOPT	2/1,456 (0.14)	5/2895 (0.17)	0.80 (0.17–3.86)	0.78
Overall			1.64 (0.98–2.74)	0.06

Nissen/Wolski Meta-analysis

Table 4. Rates of Myocardial Infarction and Death from Cardiovascular Causes.

Study	Rosiglitazone Group <i>no. of events/total no. (%)</i>	Control Group <i>no. of events/total no. (%)</i>	Odds Ratio (95% CI)	P Value
Myocardial infarction				
Small trials combined	44/10,285 (0.43)	22/6106 (0.36)	1.45 (0.88–2.39)	0.15
DREAM	15/2,635 (0.57)	9/2634 (0.34)	1.65 (0.74–3.68)	0.22
ADOPT	27/1,456 (1.85)	41/2895 (1.42)	1.33 (0.80–2.21)	0.27
Overall			1.43 (1.03–1.98)	0.03
Death from cardiovascular causes				
Small trials combined	25/6,845 (0.36)	7/3980 (0.18)	2.40 (1.17–4.91)	0.02
DREAM	12/2,635 (0.46)	10/2634 (0.38)	1.20 (0.52–2.78)	0.67
ADOPT	2/1,456 (0.14)	5/2895 (0.17)	0.80 (0.17–3.86)	0.78
Overall			1.64 (0.98–2.74)	0.06

Limitations on Meta-analysis (1)

- Trials not originally intended to explore CV outcomes.
- No patient-level source data.
- Results were based on a relatively small number of events; small changes in classification of events would alter odds ratios.
- Most trials did not centrally adjudicate CV outcomes.

Limitations on Meta-analysis (2)

- Definitions of MI were not available.
- Many trials were small and short-term, with few adverse CV events or deaths.
- From editorial of Psaty and Furberg: *“In their discussion, the authors properly emphasize the fragility of their findings.”*
- A meta-analysis is always considered less convincing than a large prospective trial designed to assess the outcome of interest.

Nissen/Wolski Meta-analysis: Conclusions

- Statistically significant finding on myocardial infarction ($p=0.03$) – many limitations, would need confirmation
- Non-statistically significant finding on cardiovascular mortality – also many limitations – but finding seems concerning (death)
- No assessment of major adverse cardiovascular events (MACE), stroke

RECORD:
**New large, randomized,
controlled, clinical trial -
conducted by GlaxoSmithKline**

RECORD: Key Features

- Aim was to show non-inferiority of combination therapy with rosiglitazone to therapy without rosiglitazone with respect to CV outcomes.
- Open-label trial – key limitation
- Primary endpoint: time-to-first cardiovascular hospitalization or cardiovascular death
- Adjudication of potential endpoint events by a Clinical Endpoint Committee (CEC), blinded to treatment assignment, but...
- Potential for ascertainment bias

Ascertainment Bias (1):

- Protocol directed that “all potential CV hospitalization...and CV death endpoints will be reported...in the CRF.”
- Reporting (or non-reporting) of potential endpoint events was at the discretion of the clinical investigator.
- Investigator was, of course, aware of treatment assignment.

Ascertainment Bias (2):

- Adverse events not considered “potential” endpoint events in investigator’s opinion would not be reported to the CEC.
- CEC’s primary charge was to “downgrade” events that the investigator deemed to be potential endpoints – to overrule her/him.
- By design, there was limited provision to search for events that investigators deemed not to be endpoint events and permit the CEC to “upgrade” them.

Ascertainment Bias (3):

- Example:
 - Consider a patient hospitalized with pneumonia and “a touch of CHF.”
Clinical investigator judged whether this was a “potential endpoint event,” i.e., a cardiovascular hospitalization.
- If operational, ascertainment bias could have affected all endpoints, with the probable exception of all-cause mortality.

Cast a Wide Net?

- Protocol could have set a low threshold for referral of adverse events for blinded adjudication, to help ensure that all endpoint events were captured, but...
- This was not how RECORD was designed/conducted.

Eight Adverse Events Not Adjudicated*

- MI reported; then deleted
- Hospitalization for pulmonary edema
- Hospitalization for intracerebral hematoma
- Hospitalization for CHF
- Hospitalization for MI
- Hospitalization for collapse; atrial fibrillation
- Hospitalization for amputation and peripheral arterial disease
- Hosp. for facial paralysis with CT scan

*** From review of Thomas Marciniak; page 95**


Eight Adverse Events Not Adjudicated*

- MI reported; then deleted
- Hospitalization for pulmonary edema
- Hospitalization for intracerebral hematoma
- Hospitalization for CHF
- Hospitalization for MI
- Hospitalization for collapse; atrial fibrillation
- Hospitalization for amputation and peripheral arterial disease
- Hosp. for facial paralysis with CT scan

*** All 8 were in the rosiglitazone group**

Some Reassurance Against Bias

- Fractions of total deaths deemed by the CEC to be CV in nature (i.e., endpoint events) were virtually the same in both treatment groups (~45%).



Is There Unequivocal Evidence of Ascertainment Bias?

- No, but cannot rule it out.
- Could one find “unadjudicated” events in the control arm? Possibly.
- To verify an extreme ascertainment bias as suggested in Dr. Marciniak’s review (8:0), one would need to examine CRFs for all subjects:
 - Pre-specified plan
 - Systematic, blinded analysis of case report forms
 - Labor intensive

RECORD: Interpretation of Findings

- With open-label design, the possibility of ascertainment bias confounds interpretation of the primary endpoint, as well as major adverse cardiovascular events (MACE: cardiovascular death, MI, stroke).

Major Adverse Cardiovascular Events (MACE) in RECORD

- Results of analyses performed by GSK:
Hazard ratio = 0.91 (95% C.I. 0.73 to 1.13)
- Dr. Marciniak's independent results:
Hazard Ratio = 1.07 (95% C.I. 0.86 to 1.33)
- Sponsor's calculated upper bound of the 95%
C.I. is <1.3
- Dr. Marciniak's upper bound slightly exceeds 1.3

Acute MI in RECORD: GSK Findings

Rosiglitazone	64/2220 (2.9%)
Control	56/2227 (2.5%)

HR 1.14, 95% C.I.: 0.80 to 1.63; p=0.47

Acute MI in RECORD: Findings of Division of Cardiovascular and Renal Products

Dr. T. Marciniak:

- Worked independently
- Applied modified criteria for acute MI, post hoc
- Included probable MIs without positive biomarkers
- Net addition of 19 MIs to the rosiglitazone group and 3 to the control group

Results: HR 1.38, 95% C.I.: 0.99 to 1.93; p=NS

Acute MI in RECORD

- Unfavorable trend for MIs in RECORD (GSK: slight trend; Dr. Marciniak: strong trend)
- Results were not statistically significant for either the GSK analysis or for Dr. Marciniak's post hoc re-adjudication and analysis.
- Findings on MI seem inconclusive
- Viewed in isolation, the results are not particularly reassuring; however,
- Findings on MI do not substantiate hypothesis in the Nissen/Wolski meta-analysis on excess MIs.

Re-adjudication of MIs in RECORD?

There may be some merit in re-adjudicating MIs in RECORD; however, re-analysis would need to be rigorous:

- Diagnostic criteria considered and agreed upon by experts in advance
- Adjudication by a committee
- Use of rigorous blinding

RECORD: All-Cause Mortality

- All-cause mortality is a “hard” endpoint
- Objective
- Insensitive to bias
- Little need for adjudication
- Verifiable, using public records, and...
- Germane because of the findings in the Nissen/Wolski meta-analysis


All-Cause Mortality: 2 GSK Analyses

- **During CV follow-up:** from the time of premature discontinuation of study medication until study end, complete withdrawal or move to “survival status” updates only, whichever was sooner.
- **Including “survival status updates:”** subjects who refused consent for protocol procedures, but consented to be followed for survival status.


All-Cause Mortality: 2 GSK Analyses

- **During CV follow-up:**
 - Rosiglitazone 111/2220 (5.0%)
 - Control 139/2227 (6.2%)
 - HR 0.79, 95% CI: 0.62, 1.02; p=0.07
- **Including survival status updates:**
 - Rosiglitazone 136/2220 (6.1%)
 - Control 157/2227 (7.0%)
 - HR 0.86, 95% CI: 0.68, 1.08; p=0.19

All-Cause Mortality: Certainty of Follow-up



All-Cause Mortality: Randomized Treatment Phase Plus 30 Days



HR = 0.79
95% C.I.:
0.54 to 1.16
Log-rank
p=0.22

At risk:	Rosi	2220	1932	1700	1521	1366	1187	553	84
	Control	2227	2056	1892	1718	1539	1344	643	99

All-Cause Mortality: Conclusions (1)

- All-cause mortality was probably the most interpretable endpoint evaluated in RECORD.
- GSK analysis is very reassuring: favorable trend for rosiglitazone on all-cause mortality.
- Some uncertainty because of subjects lost to follow-up; subjects with errors in censoring date.
- Errors in censoring date have minimal effect on results.
- Errors in vital status are critical, but veracity could be checked for subjects where there is uncertainty.

All-Cause Mortality: Conclusions (2)

- Analysis of randomized treatment phase plus 30 days is highly interpretable, largely eliminates concern regarding missing data.
- Results are very reassuring.
- Key Point: If the almost statistically significant excess in death from CV causes reported in the Nissen/Wolski meta-analysis is viewed as a hypothesis for future study, that hypothesis is not substantiated by the results of RECORD.

Conclusions on RECORD (1)

- For regulatory purposes, RECORD is viewed as a means to test two hypotheses generated by the meta-analysis of Nissen and Wolski:
 1. Rosiglitazone increases the risk of MI
 2. Rosiglitazone increases the risk of cardiovascular mortality

Conclusions on RECORD (2)

- There are some questions on the validity of the MI results because of possible ascertainment bias, but no analysis of RECORD has shown a statistically significant increase in MIs.
- GSK's results on cardiovascular mortality favor rosiglitazone, but interpretation is in question because of possible ascertainment bias.
- Results for all-cause mortality are largely free of bias, and are reassuring.

Conclusions on RECORD (3)

- RECORD's results are not as definitive as they might have been, because of:
 - a key design issue (not “casting a wide net” to ascertain endpoint events)
 - possible ascertainment bias by investigators
 - questions regarding mortality follow-up.
- Nevertheless, the results of RECORD do not substantiate the findings from the Nissen/Wolski meta-analysis on myocardial infarction and cardiovascular death.



- Thank you for your attention!